The FDA's generic dilemma

18 February 2022

By Dr Nicola Davies

The annual generic drug approvals by the US Food and Drug Administration have been falling since 2020, with 737 generics approved1 in fiscal year 2020 and 6792 in fiscal year 2021 – the latter being the lowest in five years.

The first quarter of FY 2022 saw the approval of only 150 generics,3 indicating the lowest generic approval rate in six years for 2022 if this trend continues. We discuss the reasons behind this downward trend, the implications, and the actions being taken by the FDA to address this situation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK